NCT02198339View on ClinicalTrials.gov

Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS Versus Placebo in the Treatment of a Single Attack of Acute Migraine Headache

PHASE2CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

February 28, 1999

Primary Completion Date

December 31, 1999

Conditions
Migraine Disorders
Interventions
DRUG

BIBN 4096 BS

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02198339 - Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS Versus Placebo in the Treatment of a Single Attack of Acute Migraine Headache | Biotech Hunter | Biotech Hunter